1. Are we missing the issues that really matter? A mixed method study on the prevalence, severity and experience of genitourinary symptoms and the impact on sexual function and QoL in postmenopausal women on endocrine therapy for early breast cancer
- Author
-
Friedlander, Michael, Clinical School - Prince of Wales Hospital, Faculty of Medicine, UNSW, Hickey, Martha, Department of Obstetrics and Gynaecology, University of Melbourne and The Royal Women's Hospital, Victoria, Australia, Peate, Michelle, Department of Obstetrics and Gynaecology, University of Melbourne and The Royal Women's Hospital, Victoria, Australia, De Souza E Sousa, Mariana, Clinical School - Prince of Wales Hospital, Faculty of Medicine, UNSW, Friedlander, Michael, Clinical School - Prince of Wales Hospital, Faculty of Medicine, UNSW, Hickey, Martha, Department of Obstetrics and Gynaecology, University of Melbourne and The Royal Women's Hospital, Victoria, Australia, Peate, Michelle, Department of Obstetrics and Gynaecology, University of Melbourne and The Royal Women's Hospital, Victoria, Australia, and De Souza E Sousa, Mariana, Clinical School - Prince of Wales Hospital, Faculty of Medicine, UNSW
- Abstract
The underlying hypothesis of this PhD is that the negative impact of adjuvant endocrine therapy on genitourinary symptoms in postmenopausal women with early breast cancer has been underestimated in clinical trials and that there are a myriad of genitourinary symptoms related to or exacerbated by endocrine therapies that are commonly not reported by women to their oncologists. These symptoms can be troublesome and may lead to noncompliance with treatment, especially if associated with other side effects. This issue has not been comprehensively addressed, resulting in uncertainty regarding the frequency and severity of genitourinary adverse effects associated with antiestrogens and their potential impact on quality of life (QoL). Furthermore, no studies have comprehensively and prospectively evaluated the full range of genitourinary symptoms from before therapy begins and over time. These symptoms include urinary frequency, urgency, incontinence, dysuria, prolapse among others. This study fills an important gap in the current literature and is clinically important as interventions could be used to better manage and treat many of these symptoms.A number of data collection methods and instruments were used in this project, selected on their ability to address the proposed research questions. Using a qualitative approach, with semi-structured interviews, Study I sought an in-depth insight of the genitourinary symptoms experienced by women with early breast cancer on antiestrogen therapy and an understanding on how symptoms impact on daily life and sexual function. Study II employed a prospective design, using carefully selected validated instruments, to measure the prevalence and severity of genitourinary symptoms in postmenopausal women with breast cancer (prior to adjuvant endocrine therapy) and documented the trajectory of symptoms over time. The impact of genitourinary symptoms on sexual function and QoL was also investigated. The study attempted to identify predicto
- Published
- 2015